198 related articles for article (PubMed ID: 27842569)
1. Efficacy and safety of psychostimulants for amphetamine and methamphetamine use disorders: a systematic review and meta-analysis.
Bhatt M; Zielinski L; Baker-Beal L; Bhatnagar N; Mouravska N; Laplante P; Worster A; Thabane L; Samaan Z
Syst Rev; 2016 Nov; 5(1):189. PubMed ID: 27842569
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of psychostimulant drugs for amphetamine abuse or dependence.
Pérez-Mañá C; Castells X; Torrens M; Capellà D; Farre M
Cochrane Database Syst Rev; 2013 Sep; (9):CD009695. PubMed ID: 23996457
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials.
Kishi T; Matsuda Y; Iwata N; Correll CU
J Clin Psychiatry; 2013 Dec; 74(12):e1169-80. PubMed ID: 24434105
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review.
Siefried KJ; Acheson LS; Lintzeris N; Ezard N
CNS Drugs; 2020 Apr; 34(4):337-365. PubMed ID: 32185696
[TBL] [Abstract][Full Text] [Related]
5. Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis.
Tardelli VS; Bisaga A; Arcadepani FB; Gerra G; Levin FR; Fidalgo TM
Psychopharmacology (Berl); 2020 Aug; 237(8):2233-2255. PubMed ID: 32601988
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapy for methamphetamine/amphetamine use disorder-a systematic review and meta-analysis.
Chan B; Freeman M; Kondo K; Ayers C; Montgomery J; Paynter R; Kansagara D
Addiction; 2019 Dec; 114(12):2122-2136. PubMed ID: 31328345
[TBL] [Abstract][Full Text] [Related]
7. Prescription psychostimulants as a harm reduction and treatment intervention for methamphetamine use disorder and the implications for nursing clinical practice: A scoping review of the literature.
Leidl D; Takhar P; Li H
Int J Ment Health Nurs; 2023 Oct; 32(5):1225-1242. PubMed ID: 36978242
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of naltrexone for amfetamine and methamfetamine use disorder: a systematic review of randomized controlled trials.
Lam L; Anand S; Li X; Tse ML; Zhao JX; Chan EW
Clin Toxicol (Phila); 2019 Apr; 57(4):225-233. PubMed ID: 30451013
[TBL] [Abstract][Full Text] [Related]
9. Prescription psychostimulants for the treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of randomized placebo-controlled trials.
Sharafi H; Bakouni H; McAnulty C; Drouin S; Coronado-Montoya S; Bahremand A; Bach P; Ezard N; Le Foll B; Schütz CG; Siefried KJ; Tardelli VS; Ziegler D; Jutras-Aswad D
Addiction; 2024 Feb; 119(2):211-224. PubMed ID: 37880829
[TBL] [Abstract][Full Text] [Related]
10. Association of clozapine treatment and rate of methamphetamine or amphetamine relapses and abstinence among individuals with concurrent schizophrenia spectrum and amphetamine use disorder: A retrospective cohort study.
Rafizadeh R; Frankow L; Mahmood H; Poonia S; Mathew N; Danilewitz M; Bousman CA; Honer WG; Schütz CG
J Psychopharmacol; 2023 Oct; 37(10):1040-1048. PubMed ID: 37539972
[TBL] [Abstract][Full Text] [Related]
11. A systematic review of risk factors for methamphetamine-associated psychosis.
Arunogiri S; Foulds JA; McKetin R; Lubman DI
Aust N Z J Psychiatry; 2018 Jun; 52(6):514-529. PubMed ID: 29338289
[TBL] [Abstract][Full Text] [Related]
12. Clinical management of psychostimulant withdrawal: review of the evidence.
Li MJ; Shoptaw SJ
Addiction; 2023 Apr; 118(4):750-762. PubMed ID: 36401591
[TBL] [Abstract][Full Text] [Related]
13. Mirtazapine for the treatment of amphetamine and methamphetamine use disorder: A systematic review and meta-analysis.
Naji L; Dennis B; Rosic T; Wiercioch W; Paul J; Worster A; Thabane L; Samaan Z
Drug Alcohol Depend; 2022 Mar; 232():109295. PubMed ID: 35066460
[TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapeutic agents in the treatment of methamphetamine dependence.
Morley KC; Cornish JL; Faingold A; Wood K; Haber PS
Expert Opin Investig Drugs; 2017 May; 26(5):563-578. PubMed ID: 28351169
[TBL] [Abstract][Full Text] [Related]
15. Extended-release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double-blind, placebo-controlled trial.
Miles SW; Sheridan J; Russell B; Kydd R; Wheeler A; Walters C; Gamble G; Hardley P; Jensen M; Kuoppasalmi K; Tuomola P; Föhr J; Kuikanmäki O; Vorma H; Salokangas R; Mikkonen A; Kallio M; Kauhanen J; Kiviniemi V; Tiihonen J
Addiction; 2013 Jul; 108(7):1279-86. PubMed ID: 23297867
[TBL] [Abstract][Full Text] [Related]
16. Pharmacotherapeutic strategies for methamphetamine use disorder: mind the subgroups.
Soares E; Pereira FC
Expert Opin Pharmacother; 2019 Dec; 20(18):2273-2293. PubMed ID: 31671001
[No Abstract] [Full Text] [Related]
17. Subjective and physiological effects of acute intranasal methamphetamine during d-amphetamine maintenance.
Rush CR; Stoops WW; Lile JA; Glaser PE; Hays LR
Psychopharmacology (Berl); 2011 Apr; 214(3):665-74. PubMed ID: 21072503
[TBL] [Abstract][Full Text] [Related]
18. Meta-Analysis: Risk of Tics Associated With Psychostimulant Use in Randomized, Placebo-Controlled Trials.
Cohen SC; Mulqueen JM; Ferracioli-Oda E; Stuckelman ZD; Coughlin CG; Leckman JF; Bloch MH
J Am Acad Child Adolesc Psychiatry; 2015 Sep; 54(9):728-36. PubMed ID: 26299294
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological treatments for methamphetamine addiction: current status and future directions.
Ballester J; Valentine G; Sofuoglu M
Expert Rev Clin Pharmacol; 2017 Mar; 10(3):305-314. PubMed ID: 27927042
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
